

# Ferozsons Laboratories Limited

## Condensed Interim Unconsolidated Statement of Profit or Loss (Un-audited)

For the nine months ended 31 March 2021

	Nine months ended		Quarter ended	
	31 March 2021	31 March 2020	31 March 2021	31 March 2020
	----- Rupees -----		----- Rupees -----	
Revenue - net	<b>4,749,012,271</b>	4,093,224,655	<b>1,908,555,280</b>	1,570,069,503
Cost of sales	<b>(2,780,315,890)</b>	(2,364,686,410)	<b>(1,180,412,171)</b>	(955,689,508)
<b>Gross profit</b>	<b>1,968,696,381</b>	1,728,538,245	<b>728,143,109</b>	614,379,995
Administrative expenses	<b>(290,577,170)</b>	(273,760,554)	<b>(97,950,208)</b>	(88,461,283)
Selling and distribution expenses	<b>(1,008,369,076)</b>	(1,055,784,026)	<b>(353,721,894)</b>	(332,779,022)
Other expenses	<b>(65,568,962)</b>	(48,003,434)	<b>(28,284,518)</b>	(27,920,651)
Other income	<b>123,814,797</b>	81,967,460	<b>67,561,893</b>	13,762,165
<b>Profit from operations</b>	<b>727,995,970</b>	432,957,691	<b>315,748,382</b>	178,981,204
Finance cost	<b>(17,270,535)</b>	(23,557,839)	<b>(4,515,705)</b>	(11,620,802)
<b>Profit before taxation</b>	<b>710,725,435</b>	409,399,852	<b>311,232,677</b>	167,360,402
Taxation	<b>(205,454,598)</b>	(120,285,222)	<b>(95,040,447)</b>	(56,373,963)
<b>Profit after taxation</b>	<b>505,270,837</b>	289,114,630	<b>216,192,230</b>	110,986,439
Earnings per share - basic and diluted	<b>13.95</b>	7.98	<b>5.97</b>	3.06
		<i>Re-stated</i>		<i>Re-stated</i>

Ferozsons Laboratories Limited  
Condensed Interim Consolidated Statement of Profit or Loss (Un-audited)  
For the nine months ended 31 March 2021

	Nine months ended		Quarter ended	
	31 March 2021	31 March 2020	31 March 2021	31 March 2020
----- Rupees -----				
Revenue - net	<b>6,020,708,526</b>	4,636,074,549	<b>2,339,398,643</b>	1,779,223,784
Cost of sales	<b>(3,583,672,935)</b>	(2,893,810,406)	<b>(1,468,134,799)</b>	(1,154,372,138)
<b>Gross profit</b>	<b>2,437,035,591</b>	1,742,264,143	<b>871,263,844</b>	624,851,646
Administrative expenses	<b>(333,487,670)</b>	(305,570,830)	<b>(112,726,202)</b>	(97,599,199)
Selling and distribution expenses	<b>(1,065,426,605)</b>	(1,089,686,783)	<b>(368,065,163)</b>	(342,268,517)
Other expenses	<b>(101,127,220)</b>	(47,539,879)	<b>(40,978,864)</b>	(27,457,096)
Other income	<b>144,666,556</b>	98,329,414	<b>76,800,515</b>	11,812,160
<b>Profit from operations</b>	<b>1,081,660,652</b>	397,796,065	<b>426,294,130</b>	169,338,994
Finance costs	<b>(44,033,489)</b>	(24,602,018)	<b>(23,053,025)</b>	(11,987,531)
<b>Profit before taxation</b>	<b>1,037,627,163</b>	373,194,047	<b>403,241,105</b>	157,351,463
Taxation	<b>(215,087,283)</b>	(122,641,685)	<b>(103,128,640)</b>	(56,494,451)
<b>Profit after taxation</b>	<b>822,539,880</b>	250,552,362	<b>300,112,465</b>	100,857,012
<b>Attributable to:</b>				
Owners of the Company	<b>757,950,085</b>	257,782,038	<b>282,804,137</b>	102,906,553
Non-controlling interests	<b>64,589,795</b>	(7,229,676)	<b>17,308,328</b>	(2,049,541)
<b>Profit after taxation</b>	<b>822,539,880</b>	250,552,362	<b>300,112,465</b>	100,857,012
Earnings per share - basic and diluted	<b>20.92</b>	7.12	<b>7.80</b>	2.84
		<i>Re-stated</i>		<i>Re-stated</i>